z-logo
Premium
Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy
Author(s) -
Tujios Shannan R.,
Lee William M.
Publication year - 2018
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13535
Subject(s) - medicine , intensive care medicine , liver transplantation , etiology , causality (physics) , liver failure , hepatitis , drug , transplantation , surgery , pharmacology , physics , quantum mechanics
Abstract Acute liver failure ( ALF ) requires urgent attention to identify etiology and determine prognosis, in order to assess likelihood of survival or need for transplantation. Identifying idiosyncratic drug‐induced liver injury ( iDILI ) may be particularly difficult, but the illness generally follows a subacute course, allowing time to assess outcome and find a liver graft if needed. Not all drugs that cause iDILI lead to ALF ; the most common are antibiotics including anti‐tuberculous medications, non‐steroidal anti‐inflammatory agents and herbal and dietary supplements ( HDS ). Determining causality remains challenging particularly if altered mentation is present; identifying the causative agent depends in part on knowing the propensity of the drugs that have been taken in the proper time interval, plus excluding other causes. In general, iDILI that reaches the threshold of ALF will more often than not require transplantation, since survival without transplant is around 25%. Treatment consists of withdrawal of the presumed offending medication, consideration of N ‐acetylcysteine ( NAC ), as well as intensive care. Corticosteroids have not proven useful except perhaps in instances of apparent autoimmune hepatitis caused by a limited number of agents. Recently developed prognostic scoring systems may also aid in predicting outcome in this setting.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here